Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Microbiome therapeutics go small molecule

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Nature Reviews Drug Discovery 18, 569-572 (2019)

doi: https://doi.org/10.1038/d41573-019-00122-8

Updates & Corrections

  • Correction 12 July 2019: The name of the company Kaleido Biosciences and the status of drug candidates it is developing have been corrected in Table 1, and the indication for SYN-010 has been corrected to irritable bowel syndrome with constipation. It has also been clarified that Zehna Therapeutics and Emily Balskus at Harvard University are both separately developing CutC inhibitors.

Subjects

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links